|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||144.07 / 195.81|
The S&P 500 inches higher in mixed trading Wednesday as a rally in crude helps the energy sector.
Stocks are mixed on Wednesday as financials retreat again while tech names move higher.
Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.
Stock futures edge higher on Wednesday as markets await the United Kingdom taking the first step to formally remove itself from the European Union.
Here are Wednesday's top research calls, including a downgrade of Twitter and new coverage of Facebook, Amazon and Alphabet.
Vertex to seek marketing approval for new 'teza/iva' combination therapy for cystic fibrosis patients.
This little biotech packed a big wallop on Monday as its stock nearly doubled. Here's why.
Acquiring CTP-656 from Concert Pharmaceuticals will only cost Vertex around $250 million.
The convenience of a once-daily version of Kalydeco is important to Vertex because it has the potential to simplify dosing of combination regimens the company has in development.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has signed a definitive asset purchase agreement to acquire CTP-656 from Concert Pharmaceuticals (Nasdaq: CNCE).
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Cowen Healthcare Conference on Monday, March 6 th at 2:00 p.
Jana Partners are placing three members on Tiffany's board.
Biopharma's reticence suggests that fear of Trump's tweets and threats to limit drug pricing (and cut into profits) has stopped biotech companies from standing up for what's right.
Neurocrine Biosciences, Aralez Pharmaceuticals and Qiagen were among the biotech stock movers in premarket trading on Friday.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the full-year and quarter-ended December 31, 2016.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has entered into a licensing agreement with Merck KGaA, Darmstadt, Germany for the worldwide development and commercialization of four promising...
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
Vertex Pharmaceuticals will be weighing future acquisitions and partnerships to broaden is focus beyond cystic fibrosis.
Vertex Pharmaceuticals is often mentioned as a takeover target, but the company is evaluating potential acquisitions and partnerships of its own to diversify beyond cystic fibrosis.
Vertex Pharmaceuticals provided new financial guidance for 2017 on Sunday.
Results from two studies of next-generation "correctors" for cystic fibrosis, expected in the second half of 2017, will be stock-moving events.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided an update on its business performance, including preliminary financial results for 2016 and a financial outlook for 2017, and an update on its ongoing...
Next week the J.P. Morgan Healthcare Conference becomes the hottest spot in biotech and pharma.
The biggest annual event for biotech and pharma investors starts Monday with the kickoff of the J.P. Morgan Healthcare Conference in San Francisco.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 35 th Annual J.
Jim Cramer outlines what he thinks this market needs to keep the Trump rally rolling in 2017.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.